The International Prognostic Scoring System (IPSS) is a classification tool used by doctors to help them classify your MDS and your risk of progressing to acute myeloid leukemia (AML). This tool is critical in determining the prognosis of a patient’s MDS diagnosis along with designing an appropriate treatment plan.
During this program, recorded on April 13, 2016, Dr. Ruben Mesa from Mayo Clinic begins by explaining the previous classification models such as the WHO and FAB models that have helped evolve the understanding of MDS through the IPSS and IPSS-R scoring systems tools. He then discusses the diagnostic criteria of MDS and uses a combination of lecture and case studies to present the most current thinking on the IPSS and IPSS-R scoring tools for MDS treatment. Dr. Mesa also discusses the prognostic factors that are used to determine the stage of your MDS diagnosis such as, blood counts, the appearances of your bone marrow, and chromosomal changes as well as how your healthcare provider determines your prognosis.
By the end of this program, you will understand:
- The difference between high-risk and low-risk MDS
- The importance of the IPSS and revised IPSS and how it provides a framework of your prognosis
- The role of gene mutations as additional disease factors
To download the transcript for this program:
- Click the presentation link down below
- Select Resources tab
- Download PDF of transcription